Checkpoint Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q4 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Checkpoint Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q4 2014 to Q2 2024.
  • Checkpoint Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $3K.
  • Checkpoint Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$6.98M, a 336% decline year-over-year.
  • Checkpoint Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $301K.
  • Checkpoint Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.29M, a 8196% decline from 2021.
  • Checkpoint Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $53K, a 55.8% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$6.98M $3K +$329K Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$7.31M $3K -$7.61M -100% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $301K -$8.96M -$4.58M -105% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 $4.88M $1.98M +$1.93M +3702% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $2.96M -$326K -$348K -1582% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $3.31M $7.61M +$7.6M +58431% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$4.29M -$4.38M -$4.39M -31371% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 $101K $52K +$39K +300% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $62K $22K +$9K +69.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $53K $13K $0 0% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $53K $14K -$3K -17.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $56K $13K -$1K -7.14% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $57K $13K -$16K -55.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $73K $13K -$47K -78.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $120K $17K -$14K -45.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 $134K $14K -$14K -50% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $148K $29K -$6K -17.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $154K $60K +$18K +42.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $136K $31K -$242K -88.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 $378K $28K -$15K -34.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $393K $35K -$4K -10.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $397K $42K +$24K +133% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $373K $273K +$252K +1200% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 $121K $43K +$21K +95.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $100K $39K +$15K +62.5% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $85K $18K -$13K -41.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 $98K $21K +$9K +75% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $89K $22K +$11K +100% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 $78K $24K +$11K +84.6% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $67K $31K +$364K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$297K $12K +$613K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$910K $11K +$81K Jul 1, 2016 Sep 30, 2016 10-K 2018-03-16
Q2 2016 -$991K $13K +$13K Apr 1, 2016 Jun 30, 2016 10-K 2018-03-16
Q1 2016 -$1M -$333K -$333K Jan 1, 2016 Mar 31, 2016 10-K 2018-03-16
Q4 2015 -$671K -$601K -$601K Oct 1, 2015 Dec 31, 2015 10-K/A 2017-03-21
Q3 2015 -$70K -$70K Jul 1, 2015 Sep 30, 2015 10-K/A 2017-03-21
Q2 2015 $0 Apr 1, 2015 Jun 30, 2015 10-K/A 2017-03-21
Q1 2015 $0 Jan 1, 2015 Mar 31, 2015 10-K/A 2017-03-21
Q4 2014 $0 Nov 10, 2014 Dec 31, 2014 10-K/A 2017-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.